Advantages for men with metastatic hormone-refractory prostate cancer who are no longer eligible for docetaxel therapy Abiraterone (trade name: Zytiga®) has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses...